Our Blog

We at 4bases never forget that patients are for us the most important persons and that prevention is absolutely essential in our fight against cancer. It was therefore a must for us to support the European Code Against Cancer by reminding the 12 ways to reduce cancer risk as published by the International Agency for Research on Cancer at the WHO.

Reviewing a number of enabling technologies from bioengineering to artificial intelligence this month’s paper shows how much and how fast medicine is moving away from its old “one size fits all“ mentality toward personalized and precision medicine.

We always hear about the highly celebrated Precision Medicine, but what is this in reality? An answer might be “the possibility to adopt a very personalized way to exploit at best the existing and novel therapeutic options”. A practical example is provided by the...

4bases proudly announces a new important step in its development plan. Thanks to an exclusive commercial partnership with the ILC Group, 4bases' products and services are now available to more portuguese customers. All is being done through this new partnership for...

  There is no doubt that, as we’re moving toward a more precise future for oncology, the medical community will need precise answers to new molecular diagnostic questions. While only a minority of oncology patients currently benefit from genomic matching to...

Manno, March 31, 2020 4bases SA, a swiss-based company specialized in the development, production and commercialization of reagent kits for NGS (New Generation Sequencing) is delighted to announce its new partnership with MONACO FOUNDRY, a global leader in business...

Custom panel – developed on-demand for your specific RUO or CE-IVD specific applications.

To make your choice easier and faster 4bases' company and product information are gathered in the new brochure

4bases announces its new partnership with Saphetor SA to accelerate data interpretation for targeted NGS panels. Manno, December 3st, 2019. 4bases SA, a Swiss-based company specialized in the development, production, and commercialization of reagent kits and gene...

Since the end of May 2019, around 40% of patients with HR+/HER2- breast cancer can count on a new drug developed by Novartis and approved by the FDA. This new development is another important step into the field of precision medicine. Piqray® is indeed specific to...